Fulcrum Therapeutics (FULC)
NASDAQ:FULC
US Market
Holding FULC?
Track your performance easily

Fulcrum Therapeutics (FULC) Ownership - Who Owns Fulcrum Therapeutics?

495 Followers

Fulcrum Therapeutics (FULC) Ownership Overview

6.56%13.37%1.15%12.60%66.33%
1.15% Other Institutional Investors
12.60% ETFs
66.33% Public Companies and
Individual Investors
The ownership structure of Fulcrum Therapeutics (FULC) stock is a mix of institutional, retail, and individual investors. Approximately 27.11% of the company’s stock is owned by Institutional Investors, 6.56% is owned by Insiders, and 66.33% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
May 09, 2024
xxxxxxxxxxxxx
$1831
Mar 05, 2024
Alex Sapir
President & Ceo,director
xxxxxxxxxxxxx
$491702

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$117025
Jun 30, 2024
xxxxxxxxxxxxx
$3108066

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
11,609,704Institution18.61%37,267,150
3,109,704Insider4.98%9,982,150
2,976,320Institution4.77%9,553,987
2,844,943Institution4.56%9,132,267
2,629,714Institution4.21%8,441,382
1,825,492Institution2.93%5,859,829
1,059,860Institution1.70%3,402,151
661,171Institution1.06%2,122,359
639,896Institution1.03%2,054,066
521,845Institution0.84%1,675,122

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
2,629,714Institution4.21%8,441,382
1,825,492Institution2.93%5,859,829
1,059,860Institution1.70%3,402,151
661,171Institution1.06%2,122,359
639,896Institution1.03%2,054,066
521,845Institution0.84%1,675,122
306,538Institution0.49%983,987
172,149Institution0.28%552,598
140,480Institution0.23%450,941
124,996Institution0.20%401,237

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,852,255Institution2.97%6,612,550
1,626,094Institution2.61%5,219,762
782,473Institution1.25%2,793,429
407,174Institution0.65%1,307,029
394,550Institution0.63%1,246,778
336,266Institution0.54%1,079,414
287,243Institution0.46%1,025,458
270,981Institution0.43%856,300
237,347Institution0.38%761,884
237,603Institution0.38%750,825

FAQ

Who Owns Fulcrum Therapeutics (FULC)?
According to the latest TipRanks data, approximately 1.15% of the company's stock is held by institutional investors, 6.56% is held by insiders, and 66.33% is held by retail investors.
    What percentage of Fulcrum Therapeutics (FULC) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 1.15% of Fulcrum Therapeutics (FULC) stock is held by institutional investors.
      What percentage of Fulcrum Therapeutics (FULC) stock is held by retail investors?
      According to the latest TipRanks data, approximately 66.33% of Fulcrum Therapeutics (FULC) stock is held by retail investors.
        Who owns the most shares of Fulcrum Therapeutics (FULC)?
        Peter Kolchinsky owns the most shares of Fulcrum Therapeutics (FULC).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis